We have measured changes in plasma concentration of creatine kinase MB (CK-MB) and myoglobin in 50 patients admitted to the Coronary Care Unit with chest pain of presumed cardiac origin. Eight serial blood samples were obtained in the 6 h period following admission and both CK-MB and myoglobin concentrations were measured.
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It has been established that creatine kinase MB (CK-MB) concentration measurement in serial samples obtained within 12 h of admission from patients presenting with acute chest pain allows rapid and highly efficient diagnosis of acute myocardial infarction (AMI).! ,2 It is known also that following AMI myoglobin release occurs up to 4 h earlier than CK-MB with peak levels being achieved up to 14 h earlier. 3 Although interest in myoglobin release following acute myocardial infarction is not new, dating back to 1975,4 the technology is now available to measure myoglobin concentration in serum or plasma rapidly (within minutes)." We undertook to compare the measurement of myoglobin concentration and CK-MB concentration to determine which test provided the most rapid and reliable diagnostic aid in patients admitted to the Coronary Care Unit with chest pain.
METHODS
The study was carried out on patients admitted to the Coronary Care Unit with chest pain of Correspondence: Dr W S Kilpatrick, Department of Pathological Biochemistry, Western Infirmary, Glasgow Gil 6NT, UK. presumed cardiac ongm. All patients were admitted to the Unit on the basis of clinical history and examination. Routine screening procedure was followed: the cardiac enzyme protocol in use in the laboratory was measurement of aspartate aminotransferase (AST) and total creatine kinase (CK) for three consecutive days after admission. Serial electrocardiography was also performed. The final discharge diagnosis was arrived at on the basis of segment (ST) elevation of at least 1 mm in combination with a rise in AST and CK to a level at least twice the upper limit of normal for our laboratory.
Fifty patients presenting with chest pain were studied: 35 males (age range 39 to 84 years, median 60 years) and 15 females (age range 44 to 77 years, median 69·5 years). The mean time from onset of symptoms to the time of first sample was 3· 75 h (range O' 5 to 12 h). Using the discharge diagnosis, 23 of the 50 patients were considered to have sustained an AMI, 14 males and nine females.
Blood samples were obtained from all patients on admission and 0'5,1,1'5,2,3,4 and 6 h later. Samples were centrifuged, separated and plasma stored at -20 DC until analysed for CK-MB and myoglobin concentration.
Myoglobin concentration was determined using the Behring Turbiquant Myoglobin assay system (Behringwerke AG, Diagnostica, Marburg, Germany) as recommended by the manufacturer. This is a particle enhanced assay based on the reaction between the myoglobin present in the sample and anti-myoglobin antibodies coupled to polystyrene particles. The increase in turbidity which occurs after mixing the reactants is measured photometrically. The measuring range of the assay is 50-650 JLg/L. 3 CK-MB concentration was determined using the Hybritech Tandem Icon QSR CK-MB assay system (Hybritech, Nottingham, UK) as recommended by the manufacturer. This technique utilises monoclonal antibodies to the Band M subunits in a sandwich assay. The B subunit antibody is bound to a membrane and immobilizes the CK-MB present in the sample. The M subunit antibody is linked to the enzyme alkaline phosphatase and sandwiches the already immobilized CK-MB. A substrate solution is then added, and the amount of substrate turnover is determined by measuring the reflectance of the quenched reaction at 585 nm. The response is directly proportional to the amount of enzyme specifically bound which in turn is proportional to the amount of CK-MB in the specimen. The measuring range of the assay is 2-50 JLg/L.
RESULTS
For the diagnosis of acute myocardial infarction to be made, the cut-off values used were 10 JLg/L in the case of CK-MB (previously found to give optimal separation of infarct/non-infarct patientsf and 100 JLg/L for myoglobin (upper limits for serum concentration in normal subjects range from 38-87 JLg/L depending on sex, race, and age). 6 Of the 50 patients involved in the study, 23 were considered to have sustained an AMI with the remaining 27 patients diagnosed as having either ischaemic chest pain short of infarction, or chest pain of non ischaemic origin. At each sample time on every patient, the values found for CK-MB and myoglobin were compared with the final clinical diagnosis, the patients being categorized as shown in Table 1 . Patients who received thrombolytic therapy are grouped separately. All patients given thrombolytic therapy had sustained an AMI and all time 0 samples were taken before thrombolysis was administered. Variation in patient sample numbers with time resulted from: (a) failure to collect the specimen, including patient death; and (b) samples unsuitable for analysis, turbid or grossly haemolysed samples unsuitable for the Turbitimer and turbid samples unsuitable for the Tandem Icon. If a sample failed to analyse by one method, the result found by the alternative method was dropped from further calculation.
From these data, sensitivity, specificity and efficiency of CK-MB and Myoglobin at each time period was calculated ( Table 2) admission is due to the smaller number of samples analysed, for the reasons given above. Thrombolytic therapy was subsequently given to 14 of the 23 AMI patients. On admission, CK-MB concentration was significantly elevated in four of these patients and Myoglobin concentration significantly elevated in six patients. In this thrombolysed group of patients, the mean time from onset of pain to time of first sample was 3·2h.
Of the nine patients not given thrombolytic therapy, myoglobin concentration on admission was significantly elevated in eight patients. CK-MB concentration was significantly elevated in only five patients. No patient in this group had diagnostic ECG changes on admission, ST depression being the most commonly noted abnormality. Two patients had contra-indications to thrombolytic therapy (hypertension and an active duodenal ulcer). The mean time from onset of pain to time of first sample was 7· 1 h.
DISCUSSION
A high proportion of the total CK enzyme as CK-MB isoenzyme can be highly specific for myocardial damage whereas a raised myoglobin concentration reflects damage to any skeletal muscle. It was initially felt that lack of specificity may limit the usefulness of an increase in myoglobin concentration as an early indicator of AMI. Our study has shown this not to be the case. Measurement of myoglobin concentration proved to be as specific as CK-MB concentration in the diagnosis of AMI. Possible reasons for this include: (1) CK-MB levels can also rise in skeletal muscle disease; and (2) the study population was selected, on the basis of case history, to suggest ischaemic heart disease as the diagnosis. Conditions such as severe shock, multiple trauma and severe renal failure which can raise the myoglobin concentration," were therefore eliminated.
Fourteen of the 23 AMI patients in the study received thrombolytic therapy soon after admission. It is well recognized that thrombolysis alters the kinetics of both myoglobin and CK-MB release leading to an earlier peak. It has been shown that the reduction in time to peak level is greater for CK-MB than myoglobin following thrombolysis." The timing of significant increases in both parameters are therefore of limited value in this group and for this reason their results are documented separately. The comparison between CK-MB and myoglobin concentration within the two groups remains valid. The smaller number of non-thrombolysed patients (nine patients) is a result of current clinical practice and whilst not ideal, will be encountered in any study of this nature.
It was decided to relate the timing of samples from admission rather than time elapsed from onset of symptoms for two main reasons: (1) the onset of pain does not prove permanent occlusion of the coronary artery; and (2) the onset of pain is a subjective assessment with marked patient variability. One example of the latter point is the patient who, on admission, was found to have significantly elevated concentrations of both CK-MB and myoglobin having given only a I h history of chest pain.
Our data confirm that a CK-MB concentration measurement on admission has an overall sensitivity for diagnosis of AMI of 40· 90/0 using the value of 10 I-tg/L or greater to be diagnostic of AMI. In this study, a sensitivity of 1000/0 for CK-MB was reached 4 h after admission for both the thrombolysed and unthrombolysed groups.
Myoglobin concentration, on admission, has an overall sensitivity of 63· 6% with similar specificity to CK-MB using the value of 100 I-tg/L to be diagnostic of AMI. In both the thrombolysed and non-thrombolysed patients, a sensitivity of 100% was reached I h 30 min post admission.
The lower sensitivity noted for both tests, on admission, in the group of patients who received thrombolytic therapy almost certainly reflects the shorter mean time from onset of symptoms to presentation.
In conclusion, it appears that, in patients admitted to the Coronary Care Unit on the basis of case history and clinical examination, myoglobin concentration is more effective than CK-MB concentration in the early diagnosis of myocardial infarction. In this group, a myoglobin concentration of 100 I-tg/L or greater either on admission, or if normal on admission, 90 min later, has a sensitivity of 100% and specificity of greater than 90%. This has the advantage over CK-MB concentration in providing a more rapid confirmation of the diagnosis, thus allowing, if indicated, earlier administration of thrombolytic therapy in clinically uncertain cases. It should be stressed that careful exclusion of patients with concomitant skeletal muscle damage remains an essential prerequisite for the use of the test.
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